Galectin 3 (Gal-3), which is highly over-expressed in aggressive PTC but undetectable in normal and benign thyroid conditions, is already clinically adopted as an important diagnostic biomarker to distinguish thyroid malignancy from benign nodules. Here, LGALS3 is linked to thyroid gland disorder.